Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 13, Issue 5

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Research

World J Gastroenterol. Feb 7, 2007; 13(5): 761-767
Published online Feb 7, 2007. doi: 10.3748/wjg.v13.i5.761

Table 4 Treatment modalities of patients with HCC

Treatment	n	No cirrhosis	Cirrhosis
No treatment	10	3	7
TACE, not listed for OLT	32	6	41
TACE, died waiting for OLT	15
TACE and liver transplantation	20	0	20
Liver transplantation	7	1	6
Total	84	10	74

Citation: Obed A, Beham A, Püllmann K, Becker H, Schlitt HJ, Lorf T. Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol 2007; 13(5): 761-767
URL: https://www.wjgnet.com/1007-9327/full/v13/i5/761.htm
DOI: https://dx.doi.org/10.3748/wjg.v13.i5.761

Obed A, Beham A, Püllmann K, Becker H, Schlitt HJ, Lorf T. Patients without hepatocellular carcinoma progression after transarterial chemoembolization benefit from liver transplantation. World J Gastroenterol 2007; 13(5): 761-767 [PMID: 17278200 DOI: 10.3748/wjg.v13.i5.761]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.